Advanced search
Publication Cover
Emerging Drugs Volume 4, 1999 - Issue 1
Journal homepage
21
Views
5
CrossRef citations to date
0
Altmetric
Review

PARP inhibition: a novel approach to treat ischaemia/reperfusion and inflammation-related injuries

J Zhang Guilford Pharmaceuticals, Inc., Baltimore, Maryland 21224, USA. [email protected]
Pages 209-221 | Published online: 24 Feb 2005

Bibliography

  • Bowman WC, Fitzgerald JD, Taylor JB (Eds.), Ashley Publications, London, UK (1998) 95–112.
  • Bowman WC, Fitzgerald JD, Taylor JB (Eds.), Ashley publications, London, UK (1998) 55–66.
  • Bowman WC, Fitzgerald JD, Taylor JB (Eds.), Ashley publications, London, UK (1998) 249–268.
  • SZABO C: Role of poly(ADP-ribose) synthetase in inflammation. Eur. J. Pharmacol. (1998) 350:1–19.
  • BOULIKAS T: Relation between carcinogenesis, chromatin structure and poly(ADP-ribosylation) (review). Anticancer Res. (1991) 11:489–528.
  • MURCIA G, MENISSIER-De MURCIA J: Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biol. Sci. (1994) 19:172–176.
  • UEDA K, HAYAISHI 0: ADP-ribosylation. Ann. Rev. Biochem. (1985) 54:73–100.
  • SZABO C, ZINGARELLI B, O'CONNOR M, et al.: DNA strand breakage, activation of poly(ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity in macrophages and smooth muscle cells exposed to peroxynitrite. Proc. Natl. Acad. Sci. USA (1996) 93:1753–1758.
  • BERGER NA: Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res. (1985) 101:4–15.
  • ••This paper discusses the original PARP 'suicidal hypothesis'.
  • HAUSCHILDT S, SCHEIPERS P, BESSLER WG, MULSCH A: Induction of nitric oxide synthase in L929 cells by tumour-necrosis factor alpha is prevented by inhibitors of poly(ADP-ribose) polymerase. Biochem. J. (1992) 288:255–260.
  • ZINGARELLI B, SALZMAN AL, SZABO C: Genetic disruption of poly(ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ. Res. (1998) 83:85–94.
  • •An article which describes PARP inhibitors' additional effect on abating inflammation.
  • ZHANG J, DAWSON VD, DAWSON TM, SNYDER SH: Nitric oxide activation of poly(ADP-ribose) synthetase in neurotmdcity. Science (1994) 263:687–689.
  • ••Highlights the initial discovery that PARP inhibition is neuroprotective.
  • COSI C, SUZUKI D, MILANI D, et al.: Poly(ADP-ribose) polymerase: early involvement in glutamate-induced neurotoxicity in cultured cerebellar granule cells. J. Neurosci. Res. (1994) 39:38–46.
  • WALLIS RA, PANIZZON KL, HENRY D, et al.: Neuroprotection against nitric oxide injury with inhibitors of ADP-ribosylation. NeuroReport (1993) 5:245–248.
  • ENDRES M, NAMURA SG, SALZMAN AL, et al.: Role of peroxynitrite and neuronal nitric oxide synthase in the activation of poly(ADP-ribose) synthetase in a murine model of cerebral ischemia-reperfusion. Neurosci. Lett. (1998) 248:41–44.
  • WANG Z-Q, AUER B, STINGL L, et al.: Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Gene Develop. (1995) 9:509–520.
  • ••The first paper to state that PARP-/- mice are healthy, fertile and capable of normal DNArepair.
  • ELIASSON MJL, SAMPEI K, MANDIR AS, et al.: Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nature Med. (1997) 10:1089–1095.
  • ••Details the 80% infarct reduction in cerebral ischemia for PARP-/- mice, as compared towild-type.
  • ENDRES M, WANG Z-Q, NAMURA S, et al.: Ischemic brain injury is mediated by the activation of poly(ADP-ribose) polymerase. J. Cereb. Blood Flow Metab. (1997) 17:1143–1151.
  • ••This paper discusses how PARP-/- mice are resistant to ischaemic brain injury.
  • HUANG Z, HUANG PL, PANAHIAN N, et al.: Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science (1994) 265:1883–1885.
  • LAZEBNIK YA, KAUFMANN SH, DESNOYERS S, et al.: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (1994) 371:346–347.
  • OLIVER FJ, De la RUBIA G, ROLLI V et al.: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. J. Biol. Chem. (1998) 273:33533–33539.
  • VIRAG L, SCOTT GS, CUZZOCREA S, et al.: Peroxynitrite-induced thymocyte apoptosis: the role of caspases and poly(ADP-ribose) synthetase (PARS) activation. Immunology (1998) 94:345–355.
  • PIEPER AA, VERMA A, ZHANG J, et al.: Poly(ADP-ribose) polymerase, nitric oxide, and cell death. Trends Pharmac. Sci. (1999). (In Press).
  • ENDRES M, SCOTT GS, SALZMANN AL, et al.: Protective effects of 5-indo-6-amino-1,2-benzopyrone, an inhibitor of poly(ADP-ribose) synthetase against peroxynitrite-induced glial damage and stroke development. Eur. J. Pharmacol. (1998) 351:377–382.
  • LO EH, BOSQUE-HAMILTON P, MENG W: Inhibition of poly(ADP-ribose) polymerase reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation. Stroke (1997) 29:830–836.
  • SUN A-Y, CHENG J-S: Neuroprotective effects of poly(ADP-ribose) polymerase inhibitors in transient focal cerebral ischemia of rats. Acta Pharmacol. Sinica (1998) 19 (2) :104–108.
  • ZHANG J, LI J-H, LAUTAR S: Post-ischemia protection by a potent PARP inhibitor in transient cerebral focal ischemia. Soc. Neurosci. Abstr. (1998) 24:1226.
  • LAUTAR S, PIEPER AA, VERMA A, et al.: Post-ischemia treatment with GPI 6150 diminishes poly(ADP-ribose) accumulation during ischemia-reperfusion injury in rat brain. Soc. Neurosci. Abstr. (1998) 24:1226.
  • TAKAHASHI K, GREENBERG JH, JACKSON P, et al.: Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. (1997) 17:1137–1142.
  • •This paper covers the first in vivo demonstration that a PARP inhibitor reduces infarct in cerebral ischemia.
  • TAKAHASHI K, GREENBERG JH, PIEPER AA, et al.: Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia. Soc. Neurosci. Abstr. (1998) 24:1226.
  • TOKIME T, NOZAKI K, SUGINO T, et al.: Enhanced poly(ADP-ribosyfiation after focal ischemia in rat brain. J. Cereb. Blood Flow and Metab. (1998) 18:991–997.
  • AYOUB IA, LEE EJ, OGILVY CS, et al.: Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. Neurosci. Lett. (1999) 259:21–24.
  • THIEMERMANN C, BOWES J, MYINT FP, et al.: Inhibition of the activity of poly(ADP-ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc. Natl. Acad. Sci. USA (1997) 94:679–683.
  • •An article about the cardioprotective effect of PARP inhibitors against ischemia/reperfusion injuries.
  • ZINGARELLI B, CUZZOCREA S, ZSENGELLER Z, et al.: Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase. Cardiovasc. Res. (1997) 36:205–215.
  • GRUPP IL, JACKSON TM, HAKE P, et al.: Protection against hypoxia-reoxygenation in the absence of poly(ADP-ribose) synthetase in isolated working hearts. J. Mol. Cell. Cardiol. (1999) 31:297–303.
  • WALLES T, WANG P, PIEPER A, et al.: Mice lacking poly(ADP-ribose) polymerase gene show attenuated cellular energy depletion and improved recovery of myocardial function following global ischemia. Circulation (1998) 98(Suppl.) :I–260.
  • WALLES T, PIEPER AA, LI J-H et al.: Demonstration that poly(ADP-ribose) accumulation occurs in the postischemic heart and is associated with myocardial necrosis. Circulation (1998) 98(Suppl.):1–260.
  • LAM IT: The effect of 3-aminobenzamide, an inhibitor of poly-ADP-ribose polymerase, on ischemia/reperfusion damage in rat retina. Res. Commun. Mol. Pathol. Pharmacol. (1997) 95:241–252.
  • CUZZOCREA S, ZINGARELLI B, COSTANTINO G, et al.: Beneficial effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br. J. Pharmacol. (1997) 121:1065–1074.
  • SZABO C, DAWSON VL: Role of poly(ADP-ribose) synthetase in inflammation and ischemia-reperfusion. Trends Pharmacol. Sci. (1998) 19:287–298.
  • •This is a recent review covering the beneficial effects of PARP inhibition in many animal models.
  • ELLIOTT RB, PILCHER CC, STEWART A, et al.: The use of nicotinamide in the prevention of Type 1 diabetes. Ann. NY. Acad. Sci. (1993) 696:333–341.
  • YAMMAMOTO H, UCHIGATA Y, OKAMOTO H: Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature (1981) 294:284–286.
  • RADONS J, HELLER B, BURKLE A, et al.: Nitric oxide toxicity in islet cells involves poly(ADP-ribose) polymerase activation and concomitant NAD depletion. Biochem. Biophys. Res. Comm. (1994) 199:1270–1277.
  • HELLER B, WANG Z-Q, WAGNER E, et al.: Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. J. Biol. Chem. (1995) 270:11176–11180.
  • PIEPER AA, BRAT DJ, KRUG DK, et al.: Poly(ADP-ribose) polymerase-deficient mice are protected from streptzotocin-induced diabetes. Proc. Natl. Acad. Sci. USA (1999) 96:3059–3064.
  • GALE EAM: The theory and practice of nicotinamide trials in pre-Type 1 diabetes. J. Pediat. Endocrinol. Metab. (1996) 9:375–379.
  • SHAW RC, HOLZER ME, VENZON D, et al.: Effects of a saline solution, ascorbic acid and nicotinamide upon the toxicity of endotoxin for rats. Arch. Surg. (1966) 93:562–566.
  • SZABO C, ZINGARELLI B, SALZMANN AL: Role of poly-ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite. Cir. Res. (1996) 78:1051–1063.
  • SZABO C, CUZZOCREA S, ZINGARELLI B, et al.: Endothelial dysfunction in a rat model of endotoxic shock: importance of the activation of poly(ADP-ribose) synthetase by peroxynitrite. J. Clin. Invest. (1997) 100:723–735.
  • MIESEL R, KURPISZ M, KROGER H: Modulation of inflammatory arthritis by inhibition of poly(ADP-ribose) polymerase. Inflammation (1995) 19:379–387.
  • SZABO C, et al.: Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts anti-inflammatory effects. J. Exp. Med. (1997) 186:1041–1049.
  • SEBOLT-LEOPOLD JS, SCAVONE SV: Enhancement of alkylating agent activity in vitro by PD 128763, a potent poly(ADP-ribose) synthetase inhibitor. mt. J. Radiation Oncol. Biol. Phys. (1992) 22:619–621.
  • ARUNDEL-SUTO CM, SCAVONE SV, TURNER WR, et al.: Effects of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells. Rad. Res. (1991) 126:367–371.
  • RUF A, De MURCIA JM, De MURCIA GM, et al.: Structure of the catalytic fragment of poly(ADP-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. USA (1996) 93:7481–7485.
  • MURCIA JM, NIEDERGANG C, TRUCCO C, et al.: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. USA (1997) 94:7303–7307.
  • ••This was the second article to discuss how PARP-/- mice are sensitive to genotoxic agents.
  • WANG Z-Q, STINGL L, MORRISON C, et al.: PARP is important for genomic stability but dispensable in apoptosis. Gene Develop. (1997) 11:2347–2358.
  • SHIEH WM, AME J-C, WILSON MV, et al.: Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J. Biol. Chem. (1998) 273:30069–30072.
  • BABIYCHUK E, COTTRILL PB, STOROZHENKO S, et al.: Higher plants possess two structurally different poly(ADP-ribose) polymerase. Plant J. (1998) 15:635–645.
  • BERGHAMMER HA, AUER B: A second poly-(ADPribosyl)-transferase (PARP-2) in mouse. GenBank (1998) Accession no. g3283974.
  • SMITH S, GIRIAT I, SCHMITT A, et al.: Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science (1998) 282:1484–1487.
  • LEIST M, SINGLE B, KUNSTLE G, et al.: Apoptosis in the absence of poly(ADP-ribose) polymerase. Biochem. Biophysic. Res. Comm. (1997) 233:518–522.
  • •This paper discusses how PARP-/- cells display normal apoptosis.
  • TRUCCO C, OLIVER FJ, DE MURCIA G, et al.: DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res. (1998) 26:2644–2649.
  • MASUTANI M, SUZUKI H, KAMADA N, et al.: Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA (1999) 96:3059–3064.
  • BURKART V, WANG Z-Q, RADONS J, et al.: Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta cell destruction and diabetes development induced by streptozocin. Nature Med. (1999) 5:314–319.

Websites

  • www.americanheart.org American Heart Association: Economic loss of cardiovascular diseases. (1998).
  • www.agouron.com Agouron: PARP inhibitor for cancer. (1999).
  • www.octamer.com Octamer: Platform technology. (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.